A number of other research analysts have also issued reports on the company. Credit Suisse Group reiterated a hold rating and set a $87.50 price target on shares of Henry Schein in a research report on Tuesday, August 29th. Zacks Investment Research lowered Henry Schein from a buy rating to a hold rating in a research report on Friday, June 23rd. Stifel Nicolaus reiterated a hold rating on shares of Henry Schein in a research report on Thursday, July 6th. Piper Jaffray Companies upgraded Henry Schein from a neutral rating to an overweight rating in a research report on Friday, September 15th. Finally, Jefferies Group LLC reiterated a hold rating and set a $88.50 price target on shares of Henry Schein in a research report on Friday, July 21st. One analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $93.16.
Henry Schein (NASDAQ:HSIC) opened at 79.14 on Tuesday. The stock has a market cap of $6.26 billion, a PE ratio of 11.57 and a beta of 1.10. Henry Schein has a 52-week low of $73.11 and a 52-week high of $93.50. The firm has a 50-day moving average price of $85.78 and a 200 day moving average price of $88.02.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.86 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The company had revenue of $3.06 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the previous year, the firm posted $0.82 EPS. The firm’s quarterly revenue was up 6.4% on a year-over-year basis. Equities analysts anticipate that Henry Schein will post $3.64 earnings per share for the current year.
Henry Schein announced that its board has approved a share buyback program on Monday, September 18th that permits the company to repurchase $400.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.
In other news, SVP Paul Rose sold 2,126 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total value of $366,756.26. Following the sale, the senior vice president now owns 17,841 shares of the company’s stock, valued at approximately $3,077,750.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.27% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in the company. Gs Investments Inc. acquired a new stake in shares of Henry Schein during the second quarter worth $884,000. Toronto Dominion Bank raised its position in shares of Henry Schein by 25.7% during the second quarter. Toronto Dominion Bank now owns 26,872 shares of the company’s stock worth $4,917,000 after purchasing an additional 5,487 shares during the period. WINTON GROUP Ltd raised its position in shares of Henry Schein by 14.9% during the second quarter. WINTON GROUP Ltd now owns 11,297 shares of the company’s stock worth $2,068,000 after purchasing an additional 1,465 shares during the period. Colony Group LLC raised its position in shares of Henry Schein by 1.3% during the second quarter. Colony Group LLC now owns 12,734 shares of the company’s stock worth $2,331,000 after purchasing an additional 158 shares during the period. Finally, Verition Fund Management LLC raised its position in shares of Henry Schein by 130.7% during the second quarter. Verition Fund Management LLC now owns 4,152 shares of the company’s stock worth $760,000 after purchasing an additional 2,352 shares during the period. 89.05% of the stock is currently owned by institutional investors.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.